98 related articles for article (PubMed ID: 26652429)
1. Development of PLGA-PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis.
Kumar R; Sahoo GC; Pandey K; Das VNR; Topno RK; Ansari MY; Rana S; Das P
Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():748-753. PubMed ID: 26652429
[TBL] [Abstract][Full Text] [Related]
2. Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani.
Kumar R; Sahoo GC; Pandey K; Das V; Das P
Drug Deliv; 2015 May; 22(3):383-8. PubMed ID: 24601828
[TBL] [Abstract][Full Text] [Related]
3. Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.
Costa Lima SA; Resende M; Silvestre R; Tavares J; Ouaissi A; Lin PK; Cordeiro-da-Silva A
Nanomedicine (Lond); 2012 Dec; 7(12):1839-49. PubMed ID: 22812711
[TBL] [Abstract][Full Text] [Related]
4. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.
Parvez S; Yadagiri G; Gedda MR; Singh A; Singh OP; Verma A; Sundar S; Mudavath SL
Sci Rep; 2020 Jul; 10(1):12243. PubMed ID: 32699361
[TBL] [Abstract][Full Text] [Related]
5. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
6. A new approach for the delivery of artemisinin: formulation, characterization, and ex-vivo antileishmanial studies.
Want MY; Islamuddin M; Chouhan G; Dasgupta AK; Chattopadhyay AP; Afrin F
J Colloid Interface Sci; 2014 Oct; 432():258-69. PubMed ID: 25086720
[TBL] [Abstract][Full Text] [Related]
7. Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis.
Ghosh S; Kar N; Bera T
Int J Biol Macromol; 2016 Dec; 93(Pt A):961-970. PubMed ID: 27645930
[TBL] [Abstract][Full Text] [Related]
8. Development of high efficacy peptide coated iron oxide nanoparticles encapsulated amphotericin B drug delivery system against visceral leishmaniasis.
Kumar R; Pandey K; Sahoo GC; Das S; Das V; Topno RK; Das P
Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():1465-1471. PubMed ID: 28415438
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
10. Possible mechanism of miltefosine-mediated death of Leishmania donovani.
Verma NK; Dey CS
Antimicrob Agents Chemother; 2004 Aug; 48(8):3010-5. PubMed ID: 15273114
[TBL] [Abstract][Full Text] [Related]
11. Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Aβ
Amin FU; Shah SA; Badshah H; Khan M; Kim MO
J Nanobiotechnology; 2017 Feb; 15(1):12. PubMed ID: 28173812
[TBL] [Abstract][Full Text] [Related]
12. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro study of cisplatin-loaded Fe3O4 nanoparticles modified with PLGA-PEG6000 copolymers in treatment of lung cancer.
Nejati-Koshki K; Mesgari M; Ebrahimi E; Abbasalizadeh F; Fekri Aval S; Khandaghi AA; Abasi M; Akbarzadeh A
J Microencapsul; 2014; 31(8):815-23. PubMed ID: 25090589
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasis.
Tyagi R; Lala S; Verma AK; Nandy AK; Mahato SB; Maitra A; Basu MK
J Drug Target; 2005 Apr; 13(3):161-71. PubMed ID: 16036304
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
18. Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation.
Fu YC; Fu TF; Wang HJ; Lin CW; Lee GH; Wu SC; Wang CK
Acta Biomater; 2014 Nov; 10(11):4583-4596. PubMed ID: 25050775
[TBL] [Abstract][Full Text] [Related]
19. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
20. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
Chan JM; Zhang L; Yuet KP; Liao G; Rhee JW; Langer R; Farokhzad OC
Biomaterials; 2009 Mar; 30(8):1627-34. PubMed ID: 19111339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
